Fundamental analysis of $BIVIW (BIOVIE INC.) based on financial data and reported results.

#BIVIW #BIOVIE

The Promising Growth of NF-κB Inhibitors Market - Insights and Future Prospects Explore the accelerating growth of the NF-κB inhibitors market, impacted by cancer and inflammatory diseases, and novel therapies predicted to reshape the landscape.

The Promising Growth of NF-κB Inhibitors Market - Insights and Future Prospects #None #Entero_Therapeutics #NF-κB_Inhibitors #BioVie

Biovie stock plunges after pricing $12 million public offering Investing.com -- Biovie Inc (NASDAQ:BIVI) stock plunged 43% after the clinical-stage biopharmaceutical company announced the pricing of a $12 million underwritten public offering. The offering consists of 6 million units priced at $2.00 each, with each unit comprising one share of common stock and one warrant. The warrants will be exercisable at $2.50 per share and will expire five years from issuance. The company is also offering pre-funded units as an alternative, with each consisting of one pre-funded warrant and one warrant. Biovie, which focuses on developing therapies for liver disease and neurological disorders, indicated that the proceeds will be used for working capital and general corporate purposes. The offering is expected to close on August 11, 2025. The warrants included in the offering have been approved for listing on the Nasdaq Capital Market under the symbol "BIVIW" and are expected to begin trading on August 8, 2025. ThinkEquity is serving as the sole book-running manager for the transaction. The company has granted the underwriter a 45-day option to purchase up to an additional 900,000 shares of common stock and/or pre-funded warrants and/or warrants to cover potential over-allotments. Public offerings typically result in share dilution for existing stockholders, which often leads to downward pressure on a company’s stock price. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Biovie #StockMarket #Investing #PublicOffering #FinancialNews